GILEAD SCIENCES, INC.
About GILEAD SCIENCES, INC.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $29.4B
- Net income
- $8.5B
- Total assets
- $59.0B
- Market cap
- $160.4B
- Gross margin
- 78.8%
- Operating margin
- 34.0%
- Net margin
- 28.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $29.4B
- Cost of revenue
- $6.2B
- Gross profit
- $23.2B
- Operating expenses
- $13.2B
- Operating income
- $10.0B
- Income tax
- $1.3B
- Net income
- $8.5B
- EPS (basic)
- $6.84
- EPS (diluted)
- $6.78
Balance sheet
- Total assets
- $59.0B
- Current assets
- $18.3B
- Total liabilities
- $36.4B
- Current liabilities
- $11.8B
- Shareholders’ equity
- $22.6B
Cash flow
- Operating cash flow
- $10.0B
- Investing cash flow
- -$4.8B
- Financing cash flow
- -$7.7B
- Net cash flow
- -$2.4B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $160.4B
- P/E ratio
- 18.9
- EPS (diluted)
- $6.78
- Dividend yield
- 2.56%
- Shares outstanding
- 1.3B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 22, 1992
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $8.5B in FY2025.
- Revenue grew 8% from FY2021 to FY2025.
- Gross margin of 78.8%, net margin 28.9%.
- Trading 18% below its 52-week high.
- Pays a dividend yielding about 2.56% annually.
- Valued at a price-to-earnings (P/E) ratio of 18.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GILEAD SCIENCES, INC..
Write a review
News about GILEAD SCIENCES, INC.
News & sentiment via Polygon.io
